United States: FDA Issues Draft Guidance On Data Integrity And Compliance With CGMP

The U.S. Food and Drug Administration (FDA) has recently published the draft guidance, Data Integrity and Compliance with CGMP, which comes after years of increased data integrity issues worldwide, including issues with oversight, or control, of paper records and inadequacies of audit trails. It is intended to "clarify the role of data integrity in current good manufacturing practice (CGMP) for drugs" through answers to various questions on this topic. This draft guidance applies to both human and animal drugs and biologics.

The draft guidance begins by setting forth the following definitions:

  • "data integrity" – "the completeness, consistency, and accuracy of data"
  • "metadata" – "the contextual information required to understand data" and also described as "data about data"
  • "audit trail" – "a secure, computer-generated, time-stamped electronic record that allows for reconstruction of the course of events relating to the creation, modification, or deletion of an electronic record" and also described as "a chronology of the 'who, what, when, and why' of a record"
  • "static" record formats – "a fixed-data document such as a paper record or an electronic image"
  • "dynamic" record formats – one that "allows interaction between the user and the record content"
  • "backup" – "a true copy of the original data that is maintained securely throughout the records retention period"
  • "systems" – "people, machines, and methods organized to accomplish a set of specific functions"
  • "computer or related systems" – "computer hardware, software, peripheral devices, networks, cloud infrastructure, operators, and associated documents (e.g., user manuals and standard operating procedures)"

The FDA states that the only time CGMP data may be excluded from decision making is when there is "a valid documented, scientific justification for its exclusion." To determine when such justification is present, FDA suggests reviewing Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production, §§ 211.118, 211.192 and 212.71(b). In any other situation, FDA states that "[a]ny data created as part of a CGMP record must be evaluated by the quality unit as part of release criteria."

The FDA states that every workflow, including creation of an electronic master production and control record (MPCR), must be checked through validation for its intended purpose. In addition, appropriate controls must be utilized to "assure that changes to computerized MPCRs, or other records, or input of laboratory data into computerized records, can be made only by authorized personnel." Where possible, this should be done by technical means, such as limiting permissions to change settings or data. For smaller operations or facilities, alternate control strategies may be used, such as having a second person review settings and content. As such, shared login accounts are not to be used. Instead, the appropriate controls should assure only authorized personnel can make changes and that such actions are attributable to a specific individual. Also, if blank forms are used (including worksheets, laboratory notebooks and MPCRs), they must be controlled by the quality unit or by another document control method.

Any data generated to satisfy a CGMP requirement is considered to be "a CGMP record." Therefore, according to this draft guidance, the FDA requires this data to be documented or saved at the time of performance to be in compliance with CGMP requirements. It is important to note that the FDA finds it unacceptable to record data on paper that will be thrown out after it is incorporated into a permanent notebook. Similarly, it is unacceptable to store electronic data in temporary memory or in a manner that allows for manipulation of data before being permanently recorded. Automatically saved electronic data in temporary memory do not meet the CGMP requirements under this draft guidance.

Audit trails are part of the associated record and the "[p]ersonnel responsible for record review under CGMP should review the audit trails that capture changes to critical data associated with the record as they review the rest of the record." More specifically, these audit trails should be "reviewed with each record and before final approval of the record." This regular review should be done for at least the following changes: the change history of finished product test results, changes to sample run sequences, changes to sample identification and changes to critical process parameters.

For copies, "[e]lectronic copies can be used as true copies of paper or electronic records, provided that the copies preserve the content and meaning of the original document." Likewise, a paper printout or static record of the complete record may satisfy the retention requirements. However, "true copies of dynamic electronic records may be made and maintained in the format of the original records or in a compatible format, provided that the content and meaning of the original records are preserved and that a suitable reader and copying equipment" are readily available. For these dynamic documents, a printout or static record would not be appropriate, as they do not preserve the format of the original record.

If there is any indication of a quality issue, such as suspected or known falsification or alteration of a record, the draft guidance states that it must be formally and fully investigated under the CGMP quality system to determine the following: (1) the effect of the event on patient safety, product quality and data reliability; and (2) the root cause. The purpose of this investigation is to ensure the necessary corrective actions are taken.

To show that a problem has been rectified, the FDA encourages "hiring a third party auditor, determining the scope of the problem, implementing a corrective action plan (globally), and removing at all levels individuals responsible for problems from CGMP positions."

Shortly after this draft guidance was issued, the FDA issued a warning letter to Sri Krishna Pharmaceuticals Ltd., finding deficiencies in four general areas of CGMP: (1) failure to include complete data in laboratory notebooks; (2) failure to exercise appropriate control over computer systems; (3) failure to establish adequate written procedures for production and process controls; and (4) failure in certain instances to follow established written procedures. In order to remedy these deficiencies, the FDA requested that Sri Krishna take the following actions: (1) have a qualified third party carry out a comprehensive investigation into the extent of the inaccuracies in the records and reporting, as well as conduct interviews of employees; (2) perform a risk assessment of potential effects on the quality of the drugs and the risk to patients; and (3) complete a management strategy that includes details of global corrective and preventive action plans. This appears to be a trend in the FDA's warning letters and indicates that the FDA is anticipating long-term measures to be part of a corrective action plan that includes enhancing procedures, systems and "human resources."

Noncompliance with data integrity CGMPs may result in significant sanctions, including consent decrees, import alerts or the like.

If you have any questions about this Alert, please contact Frederick (Rick) R. Ball, Carolyn A. Alenci, any member of the Pharmaceutical, Medical Device, Pharmacy and Food industry group or the attorney in the firm with whom you are regularly in contact.

Disclaimer: This Alert has been prepared and published for informational purposes only and is not offered, nor should be construed, as legal advice. For more information, please see the firm's full disclaimer.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions